Denali Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Denali Therapeutics Inc's ROI in the second quarter of 2026?
Denali Therapeutics Inc achieved a return on average invested assets (ROI) of 0.09 % in its second quarter of 2026, this is above DNLI's average return on investment of -7%.
Denali Therapeutics Inc invested over the 12 months ending in its second quarter of 2026 $1,059 million

ROI fell compared to the first quarter of 2026, despite the net income growth of % from the first quarter of 2026.

Within the Healthcare sector 186 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 2450, from total ROI ranking in the first quarter of 2026 at 2902.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-13.44 %	-19.12 %	-23.34 %	-16.53 %	-5.53 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	1,068	1,156	1,047	965	1,075
Return On Investment (TTM)	0.09 %	0.42 %	-0.01 %	-6.77 %	-4.6 %
DNLI's Overall Ranking	# 2450	# 2902	# 3049	# 2934	# 2802
Seq. Investment Change TTM	-0.17 %	-0.55 %	-5.02 %	-8.2 %	-6.73 %
Seq. Net Income Change TTM	-77.67 %	-	-	-	-
Net Income (TTM) in Millions	1	4	0	-76	-56

DNLI Company Profile >> Back to DNLI Roi Comparisons >> See Annual DNLI Return On Investment

Return On Investment DNLI's Ranking
Within:	No.
Industry	# 19
Sector	# 187
Overall	# 2450

Return On Investment Statistics
High	Average	Low
30.56 %	-7 %	-37.66 %
(Jun 30 2023)		(Dec 31 2021)

News about Denali Therapeutics Inc Return on Investment ROI

Denali Therapeutics Charts Ambitious Course for 2025 Amid Financial Challenges and Pivotal FDA Discussions on Hunter Syndrome Therapy,

January 13, 2025

Denali Therapeutics Sets Ambitious 2025 Milestones Despite Financial StrugglesDenali Therapeutics Inc. a biotech firm focused on developing therapies for neurodegeneration and lysosomal storage diseases, recently outlined its key anticipated milestones for 2025. The company’s Chief Executive Officer, Ryan Watts, Ph.D. is scheduled to present these goals at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. This presentation comes amid the backdrop of significant financial challenges, as Denali has reported a cumulative net loss of $366 million for the 12 months ending in the third quarter of 2024. This translates to a concerning negative return on investment (ROI) of -27.29%. In terms of financial performance, Denali s position is not favorable compared to its peers within the healthcare sector, as 337 other companies boasted a higher ROI during the same period. However, there is a slight improvement observe in Denali s overall ranking, with its ROI increasing from 3476 in the second quarter of 2024 to 3018 by September 30, 2024. This indicates a progressing position, albeit off a low base.One of the key highlights for Denali Therapeutics is its recent engagement with the U.S. Food and Drug Administration (FDA) regarding Tividenofusp Alfa (DNL310), the company’s investigational treatment for Mucopolysaccharidosis Type II (MPS II), alternatively known as Hunter Syndrome. This meeting was instrumental in paving the way for the company to seek accelerated approval from the FDA. This pathway is particularly valuable as it may expedite patient access to treatments that address significant unmet medical needs.

Financial Statements
Denali Therapeutics Inc's II. Quarter Investments	$ 1,068 Millions	DNLI's Balance sheet
Denali Therapeutics Inc's II. Quarter Income	$ -128 Millions	Quarterly DNLI's Income Statement
DNLI's Income by Division		See DNLI's Income by Division

DNLI Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	1,047	1,272	1,076	1,096	1,026
Y / Y Investment Growth	-17.73 %	18.22 %	-1.86 %	6.86 %	-33.06 %
Net Income in Millions	0	0	0	0	1
Y / Y Net Income Growth	-	-	-	-	-99.6 %
Annual Return On Investment	-0.01 %	-0.01 %	-0 %	-0 %	0.06 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
DNLI's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for DNLI's Competitors
Subscribers only: Roi for Denali Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for DNLI's Customers

Other Ratios
DNLI's Roa	DNLI's Inventory Turnover Ratio	DNLI's Growth Rates	DNLI's Dividend Statistics
	DNLI's Profitability Ratios	DNLI's Asset Turnover Ratio	DNLI's Dividend Growth
DNLI's Roe	DNLI's Valuation Ratios	DNLI's Financial Strength Ratios	DNLI's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector	ROI
Champions Oncology Inc	0.18 %
Talkspace Inc	0.16 %
Denali Therapeutics Inc	0.09 %

Date modified: 2026-09-06T12:18:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.